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Abstract
HIV-1 protease represents an appealing system for directed enzyme re-design, since it has various different endogenous
targets, a relatively simple structure and it is well studied. Recently Chaudhury and Gray (Structure (2009) 17: 1636–1648)
published a computational algorithm to discern the specificity determining residues of HIV-1 protease. In this paper we
present two computational tools aimed at re-designing HIV-1 protease, derived from the algorithm of Chaudhuri and Gray.
First, we present an energy-only based methodology to discriminate cleavable and non cleavable peptides for HIV-1
proteases, both wild type and mutant. Secondly, we show an algorithm we developed to predict mutant HIV-1 proteases
capable of cleaving a new target substrate peptide, different from the natural targets of HIV-1 protease. The obtained in
silico mutant enzymes were analyzed in terms of cleavability and specificity towards the target peptide using the energy-
only methodology. We found two mutant proteases as best candidates for specificity and cleavability towards the target
sequence.
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Introduction
Proteases represent a class of enzymes ubiquitous in all living
organisms, with multiple applications in industry and biotechnol-
ogy research [1–3]. There is thus interest in designing new
proteases capable of cleaving specific peptide sequences [4]. HIV-
1 protease (PR) represents an attractive starting structure for
directed enzyme re-design, since it is known to cleave a variety of
sequences. PR is the enzyme responsible for processing the gag –
pol fusion polyproteins of the HIV virus [5]. PR is an aspartic
protease [6–8] and is a homodimer where each chain is composed
of 99 residues. Wild type PR (WT-PR) is very specific for the
endogenous cleavage sequences of the polyprotein (endogenous
substrate peptides, Table S1 in File S1), even if the source of this
specificity is still not completely clear. A series of other non-
endogenous peptides have also been found to be cleaved by PR.
The latest hypothesis on the origin of this specificity, called
dynamic substrate envelope [9,10], states that peptides fitting into
the protease cavity through a certain number of hydrogen bonds
will be bound and possibly cleaved nearly regardless of their amino
acid composition. In fact, there is no clear trend in amino acid
sequence (e.g. a negatively charged amino acid in position P1 or a
hydrophobic one in position P29). This suggests that with few
mutations PR could be made to cleave other target peptide
sequences in a specific manner.
Many computational studies on PR, both wild type (WT) and
drug resistant mutant enzymes, are aimed at elucidating the
affinity of the enzymes towards endogenous substrates and
inhibitors to be used as drug candidates [11–14]. Recently
Chaudhury and Gray [15] published a computational algorithm
specifically tailored for PR and aimed at the identification of the
specificity determining residues. The algorithm is based on
PyRosetta [16], a python script-based interface to Rosetta [17].
Thanks to the algorithm the authors were able to predict accurate
protease – substrate complex structures (within 1.1 A˚ rms of the
corresponding crystal structure) and introduced an energetic
discrimination of cleavable peptides. More recently Alvizo et al.
[18] employed computational methods to re-engineer a mutant
PR (Pr3) more specific for one of the endogenous peptide
sequences over two others.
The first aim of this study is to develop an energy-only based
methodology to discern cleavable and non cleavable peptides for
PRs, WT and mutant. This methodology is based on the
qualitative evaluation of PR: peptide complexes binding energies
and is derived from the algorithm developed by Chaudhury and
Gray. The second aim is to search and define an algorithm to
predict mutant PRs capable of cleaving a specific target peptide
sequence different from any endogenous substrate. We use our
cleavability discerning methodology on the suggested mutant
proteases, in order to define the best guess in terms of specificity
towards the peptide sequence. In other words, the sought after
mutant structure has to show better and worse binding towards the
target and endogenous peptides, respectively, than WT-PR. To
the best of our knowledge ours is the first study aimed at predicting
a mutant PR capable of cleaving specifically a non endogenous
peptide sequence.
The paper is organized as follows: first, we present our
computed binding energies for known cleavable and non-cleavable
peptides bound to WT-PR, selected peptides bound to a set of
single, double and triple mutants (Pr3 set) derived from Pr3 as
developed by Alvizo et al., and a set of known mutant PRs and
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peptide derived from drug resistance (DR set) studies [19–21].
Secondly, we present two different versions of our algorithm to
determine mutant PRs that will cleave the sequence
HFLSF*MAIP, where the * symbol indicates the desired cleaving
site. A discussion about the best strategy to suggest mutant
enzymes follows. The conclusions summarize the main findings of
the paper, followed by a detailed description of the employed
computational methods.
List of Abbreviations
PR HIV-1 protease.
WT-PR Wild type HIV-1 protease.
mutant PR Mutant HIV-1 protease.
Pr3 set Set of mutant proteases derived from Pr3, a mutant
protease developed by Alvizo et al. These were heterodimer
proteases.
DR set Set of mutant proteases derived as a subset of HIV-1
proteases that have been found to be drug resistant. These were
homodimer proteases.
Results and Discussion
Development of a Cleavability Test
In general, the activity of an enzyme towards two similar
substrates is regulated by (i) the strength of the enzyme-substrate
binding and (ii) the efficiency of the enzymatic reaction. The two
processes are regulated by two constants, usually indicated as km
and kcat, respectively. The overall enzymatic efficiency is given by
the ratio of these two constants. The dynamic substrate envelope
hypothesis [10] suggests that if a peptide is bound to PR it will be
cleaved. Thus, we decided to evaluate the binding energy of
different peptides to PR, which can be correlated to km. We then
compared the computed binding energies to PR of known
cleavable and non cleavable peptides, to be correlated to
corresponding ranges of binding energies. By so doing we
disregarded kcat, that is we did not consider possible effects from
the enzymatic reaction.
The cleavability test was developed by considering binding
energies of WT-PR with its endogenous and known cleavable
substrates and known non-cleavable peptides. Afterwards we
investigated the reliability of the test with mutant PRs (the Pr3 set)
when binding PR endogenous substrates. Finally, we assessed the
test on mutant PRs (the DR set) when binding mutant substrates.
The complete methodology for evaluating binding energies is
described in the computational methods section. In brief, it is
composed by a structure optimization algorithm, followed by an
energetic re-evaluation of the obtained structures. In the following
paragraphs we evaluate our methodology in terms of binding
energies versus cleavability for: (1) WT-PR and its endogenous
substrates and known cleavable and non-cleavable peptides, (2) the
Pr3 set of mutant PRs and endogenous substrates and (3) the DR
set with wild type and mutated endogenous peptides. Binding
energies were computed also for WT-PR and all mutant PRs in
complex with octa-alanine (poly-Ala) and octa-arginine (poly-Arg)
peptides to test for aspecific binding.
(1) Table 1 reports the computed binding energies of the set of
known cleavable endogenous peptides of WT-PR. The sequence
of the tested endogenous cleavable peptides is reported in Table
S1 in File S1. Alongside the endogenous peptides, a set of 59
known cleavable peptides was also tested. The sequence of the 59
tested non-endogenous cleavable peptides was obtained as
previously described [15,22–26]. Table S5 in File S1 reports the
computed binding energies to WT-PR and Table S2 in File S1 the
sequences of these non-endogenous peptides. Table S6 in File S1
reports the computed binding energies of a set of peptides
supposedly non-cleavable by WT-PR. The sequence of the 43
tested non-cleavable peptides was obtained as previously described
[15,26,27] and is reported in Table S3 in File S1.
We performed a Mann-Whitney’s U test [28] to compare the
computed binding energies, and found a significant difference
between the cleavable and non-cleavable sets (p &10{7), as
reported in Table 2. Thus, we deemed the binding energy
criterion sufficient to achieve discrimination. We further analyzed
the computed binding energies through an ROC plot [29] relative
to different cutoff values, so as to differentiate between cleavable
and non-clevable peptides. The plot is reported in Figure 1, and
the relative data in Table S11 in File S1. The computed area
under ROC [30] is 0.79 and 0.80 for FMO and RosettaDock
energies, respectively, being the values of 0.50 and 1.00 typical
correspondingly of a useless and a perfect test. Through the ROC
plot, we found the best cutoff values discerning cleavable and non-
cleavable peptides as those closest to (0, 1), which represents the
theoretical perfect test. We found that cutoff values of 225 kcal/
mol and 23 kT are best at discerning FMO and RosettaDock
computed binding energies, respectively. Both FMO and Rosetta-
Dock perform well in computing binding energies capable of
Table 1. Computed binding energies of WT-PR and cleavable endogenous peptides.
Substrate Peptide FMO (kcal/mol) RosettaDock (kT) exp Km (mM) [22]
MA-CA 257 29 0.15
CA-p2 252 26 0.01
p2-NC 272 24 0.05
NC-p1 268 23
p1-p6 247 1
p6pol-PR 241 26
TF-PR 262 25 v0.01
PR-RTp51 264 27 0.07
RTp51-RTp66 268 212 0.04
RTp66-INT 262 26
RH-IN 263 210 0.006
doi:10.1371/journal.pone.0095833.t001
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discerning cleavable and non-cleavable peptides. However, Figure
S1 in File S1 shows that there is no apparent correlation between
FMO and RosettaDock computed binding energies. Thus, we
repeated the Mann-Whitney’s U test and ROC analysis excluding
the set of non-endogenous known cleavable peptides binding
energies. The rationale behind this analysis is that we expect WT-
PR to bind the endogenous peptides with higher affinity, as
opposed to the broader range of the complete cleavable set,
characterized only by cleavability and not specificity. Consequent-
ly, we assume that the endogenous peptides set have better binding
energies, than the complete set of cleavable peptides. The Mann-
Whitney’s U test (Table 2) shows that the RosettaDock based
binding energies are in this case two orders of magnitude worse
than FMO at discerning cleavable and non-cleavable peptides.
The relative ROC plot (Figure S2 in File S1) shows as well that the
FMO data performs better than RosettaDock, in terms of more
strict best cutoff value and larger area under the ROC. Thus, we
concluded that FMO computed binding energies are better than
RosettaDock ones since are capable of discerning expected effects,
such as the usage of a better performing subset of peptides. In the
rest of this paper we will discuss only binding energies computed
through FMO energy re-evaluation.
From Table 1 it is expected that WT-PR exhibits qualitatively
different binding to the poly-protein substrates, given their
computed binding energies ranging from 241 for the binding
of p6pol-PR to 272 kcal/mol for p2-NC, with an average value of
260 kcal/mol. However, available experimental Km values [22]
do not show any trend similar to the computed data. Still, one has
to remember that these computed binding energies should be
considered only qualitatively and only compared to others
obtained in the same manner. See the Computational Methods
section for further details. Furthermore, the span of both
computed energies for which experimental data are available
(20 kcal/mol) and the Km values (2 orders of magnitude) is too
small to allow a clear trend. The computed binding energies for
the set of cleavable non-endogenous peptides (Table S5 in File S1)
span a wide range of values, from 22 to 286 kcal/mol, with
average 240 kcal/mol. These peptides not being the natural
target of WT-PR may account for this large span. The average
computed binding energy for all cleavable peptides is 243 kcal/
mol. The computed binding energies for the non-cleavable set of
peptides (Table S6 in File S1) span an even wider range of values
than those of the cleavable ones. Some PR – peptides complexes
show positive energies. The majority (56%) of the computed
binding energies are in the range 235–0 kcal/mol. However, a
few peptides show a binding energy to WT-PR similar to those of
the cleavable peptides.
(2) Recently Alvizo et al. [18] suggested through computational
means a triple mutant (Pr3) with increased binding capability
towards the endogenous RTp51-RTp66 cleavage sequence
peptide compared to that towards other two cleavage sequences
CA-p2 and p2-NC. The efficiency of Pr3 in cleaving preferentially
RTp51-RTp66 was later experimentally verified. Pr3 was made by
tethering a mutated chain of protease (A28S, D30F, G48R) to a
wild type one. For comparison with our predicted mutant PRs,
Table 3 reports our computed binding energies for the Pr3 three-
fold mutant, as well for simpler one- and two-fold mutant PRs
derived from Pr3 (Pr3 set), as compared to WT. Note, however,
that experimental data are available only for the three-fold mutant
PR. In our calculations, Pr3 set carried mutations only on chain A,
while still being formed by two separate chains. We expected to
find that Pr3 computed binding would be stronger towards
RTp51-RTp66, while weaker towards CA-p2 and p2-NC,
compared to WT-PR. The computed binding energies of the
Pr3 set show that the mutant enzymes often have higher affinity
for the desired RTp51-RTp66 peptide compared to CA-p2 and
p2-NC. Most notably the double mutant A28S/G48R has a
stronger computed binding energy towards the target peptide than
WT-PR, while lower for the other two endogenous substrates. The
binding energy test indicates that A28S/G48R (for which there is
no experimental data available) would have been a more successful
mutation than Pr3. Nevertheless, the possibility of using the
binding energy test with mutant PRs was found viable.
(3) Finally we decided to apply the binding energy test to series
of mutant PRs binding mutant endogenous substrates. Thus, we
evaluated the binding energies of drug resistant HIV-1 proteases
towards wild type and mutant substrate peptides. It has been
found that mutations of the cleavage sites are correlated to
mutations of the protease, often leading to drug resistance. We
analyzed the K436R and A431V mutations of the NC-p1 Gag
substrate peptide cleavage sequence in relation to a series of single
mutations and one double mutation of HIV-1 protease (DR set). It
has been reported [19] that a K436R mutation increases resistance
to protease inhibitor drugs when combined with I50 V, I84 V and
I84 V/L90M PR mutations, while the A431V mutation results in
a more efficient PR regardless of other mutations. We expected
that the more efficient mutant PR – mutant peptide combinations
were also characterized by stronger binding energies. Table 4
reports the results of our binding energy test for the DR set. Our
methodology indicates cleavability for all combinations of mutant
PRs and mutated NC-p1 substrate peptides. While there are some
fluctuations in the binding energies, no clear pattern arises that
can be related to the experimental findings. Possibly, the increased
efficiency of drug resistant mutant proteases towards mutated
peptides is related to kcat. As previously stated, the effects of this
constant are not considered by the present approach. Nevertheless,
the binding energy test was found suitable also for combinations of
mutant PRs with any peptide.
Prediction and Analysis of Mutant PRs
The second aim of this study was to develop a computational
methodology for the design of a mutant PR. The sought after
Figure 1. ROC plot comparing different cutoff values for
binding energies computed through FMO energy re-evalua-
tion or RosettaDock energy function. The values for each method
closest to the theoretical optimum (0,1) are highlighted. The computed
area under the ROC curve is 0.79 and 0.80 for FMO and Rosetta,
respectively. The raw data is reported in Table S11 in File S1.
doi:10.1371/journal.pone.0095833.g001
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enzyme had to be capable of cleaving a new target substrate
different from the endogenous ones. The obtained mutant PR
should also be specific for the target peptide sequence compared to
the endogenous peptides. The chosen sequence for the target
peptide was HLSF*MAIP, where the * symbol indicates the
desired cleaving site. The sequence was extracted from that of
k-casein. Once candidate mutant PRs were obtained, we
employed the binding energy test to asses the enzymes cleaving
capabilities. The possibility of an increase in cleaving capability
towards the target substrate was asserted by differences in binding
energy between WT-PR and mutant PRs. We evaluated the
binding energies of mutant PRs in complex with the TF-PR
peptide, used as a starting template (see the Computational
Methods section), and the CA-p2 and p2-NC peptides (for selected
mutant PRs) in order to test the specificity of our mutant PRs.
The mutant-generating algorithm is described in details in the
Computational Methods section. Two main strategies (Strategy1
and Strategy2) were employed for generating mutant PRs. In
Strategy1, the side chains of only the 6 residues previously
indicated as specificity determining [15] were allowed to change.
The analysis of the binding energies of the mutant PRs generated
by Strategy1 found the enzymes insufficient to perform the desired
scope. This prompted us to further develop the algorithm. In
Strategy2, the side chains of 26 residues were allowed to change.
See the Computational Methods section for further details on the
residues choice. The analysis of the binding energies of these
mutant PRs found some of the predicted enzymes to be adequate
to cleave the desired target sequence.
Tables S7 and S8 in File S1 reports the Strategy1 mutant PRs
(M1–M16) and their computed binding energies towards the
targetpeptide and TF-PR, CA-p2 and p2-NC endogenous
peptides. Among these mutant PRs, M5 shows the strongest
binding energy towards the target peptide. However it has to be
noted that the computed binding energy of M5 towards the TF-
PR peptide (used as a starting template for all mutant enzymes) is
also stronger with respect to WT. Possibly M5 is simply a better
generic binder. To verify this hypothesis we tested M5 as a binder
also for other two endogenous peptide sequences, CA-p2 and p2-
Table 2. Comparison of WT-PR computed binding energies.
RosettaDock Energy Function FMO Energy Re-evaluation
Average endogenousa 26 (kT) 260 (kcal/mol)
(Standard deviation) (3) (kT) (10) (kcal/mol)
Average all cleavableb 25 (kT) 243 (kcal/mol)
(Standard deviation) (3) (kT) (22) (kcal/mol)
Average non cleavablec 21 (kT) 215 (kcal/mol)
(Standard deviation) (4) (kT) (28) (kcal/mol)
U test probability (all cleavable VS non-cleavable) 1:46:10{7 2:21:10{7
U test probability (only endogenous VS non-cleavable) 3:49:10{4 6:16:10{6
aTable 1.
bTable 1 plus Table S5 in File S1.
cTable S6 in File S1.
Energies were computed with the standard RosettaDock energy function, as described in [15] and with the FMO re-evaluation. A Mann-Whitney’s U test probability was
evaluated by comparing the binding energies of the set of endogenous peptide against the non-cleavable and the entire set of cleavable peptides against the non-
cleavable. The FMO based binding energies are more clear in discriminating cleavable and non cleavable peptides than the Rosetta based ones.
doi:10.1371/journal.pone.0095833.t002
Table 3. FMO computed binding energies of HIV-1 protease WT and Pr3 set of mutant PRs.
PR Peptides
RTp51-RTp66 poly-Ala poly-Arg TF-PR CA-p2 p2-NC
WT-PR 268 215 241 262 252 272
Single mutant
A28S 265 212 235 241 213 267
D30F 248 21 0 27 24 243
G48R 266 244 227 255 215 243
Double mutant
A28SD30F 244 216 30 235 222 255
A28SG48R 296 216 254 235 214 260
D30FG48R 276 3 18 219 21 254
Triple mutant
A28SD30FG48R 242 221 12 232 212 263
Computed binding energies (kcal/mol) of WT and mutant HIV-1 proteases in complex with RTp51-RTp66, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides.
doi:10.1371/journal.pone.0095833.t003
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NC. Compared to WT-PR, M5 has weaker binding energy for the
former peptide, but equal for the latter. In conclusion, M5 is not
predicted to be more specific for the target sequence than for the
endogenous peptides. Moreover, M5 was not directly predicted
through Strategy1, but as a homodimeric derivative of M2, which
shows only a small improvement in binding of the target peptide.
All other mutant PRs suggested by Strategy1, M1–M4 and M6–
M16, were found having a weak binding energy towards the target
peptide, with some of them showing prominently positive binding
energies. It can be concluded that Strategy1 is unsatisfactory at
predicting a mutant PR with an increased and specific affinity
towards the target peptide. This is possibly due to the fact that
allowing only six residues to change is too strict a condition to
achieve a suitable mutant PR.
Thus, we decided to further improve the mutation algorithm by
including more residues among those that can be changed. The six
generations of mutant PRs computed through our Strategy2
mutant algorithm are presented in Table 5. We refer to them as
generations since at each macro step of the algorithm the lowest in
energy (as computed with the standard RosettaDock energy
function) structure was used as starting point for the next step. The
sixth generation (M23) did not produce any new change with
respect to the fifth (M22), and the algorithm was consequently
terminated. For each generation the structure with the lowest
absolute energy was further optimized. After generation 1 two
mutant structures were chosen (M17 and M18) since they are very
close in energy (as evaluated with the RosettaDock energy
function, data not shown) but relatively different as mutation
sites. In addition, an extra mutant PR (M24) was generated as
homodimer of M22. The computed binding energies of the
Strategy2 mutant PRs (M17–M24) are shown in Table 6. All
Strategy2 mutant PRs show a binding energy towards the target
sequence two to four fold stronger than WT-PR, with M17
displaying the strongest binding energy. However, as for M5,
binding energies towards the template peptide TF-PR as well as
CA-p2 and p2-NC are also stronger than WT. Possibly M17 is
also a good but generic binder. Through the subsequent
generations of mutant proteases, at last M22 shows a binding
energy towards the target peptide more than three fold stronger
than WT, while the computed binding energy towards the natural
endogenous substrates is weaker than WT. Similar results were
obtained for its homodimer M24. M22 and M24 show binding
energies below the cutoff value of 225 kcal/mol, and thus
represent the best candidates to be further studied experimentally.
We compared the structures of WT-PR and M24 as optimized
while binding the target peptide. Figure 2 reports the superim-
posed backbones of the two enzymes after structure alignment.
The two computed structures are quite coincident. Hence, it is
expected that M24 should retain the main structural features of
the wild type enzyme. We also tried to analyze the choice of
changed residues. Figure 3 shows that the residues that were
changed from WT-PR to M24 are disposed all around the bound
peptide. Figures S3–S14 in File S1 compare each residue that
differs between WT-PR and M24, while bound to the target
peptide. Although it is evident that the A28S substitution on chain
A introduces a hydrogen bond between the residue and the side
chain of the serine in the peptide (Figure S3 in File S1), the other
substitutions are less easily rationalized. On going study aims at
elucidating the role of the other residues substitutions.
It is interesting to note that Strategy2 mutated only 7 out of the
26 residues that were set as mutable in the method. It is also worth
noting that of the 7 residues (A28, D30, K45, I50, P81, V82, I84)
suggested by Strategy2 in the various mutant generations, A28,
K45, P81 are not included in the set of major mutations site of
HIV-1 protease responsible for drug resistance [31], that is: D30,
V32, M46, I47, G48, I50, I54, Q58, T74, L76 V82, N83, I84,
N88, L90. A28, K45, and P81 together with I50 are also not
included in the specificity determining residues set [15]. However,
A28 was located by Alvizo et al. for the Pr3 mutant [18]. We
envision Strategy2 also as a tool to locate those residues most
involved in binding a given substrate peptide.
From the analysis of the different PRs, mutant and wild type,
and their binding energies, it is worth to note that WT-PR has a
certain affinity with the octa-arginine peptide. Its computed
binding energy is at the limit to consider the octa-arginine peptide
as cleavable by WT-PR. Possibly this relatively strong binding is
given by very few interactions. Accordingly, the single D30F
change on chain A, that is changing one negatively charged
residue into an aromatic hydrophobic one, is able to drop the
computed binding energy to 0, as shown in Table 4. The currently
going analysis of the residue by residue interactions for the
modified side chains will give further information also on this
aspect of the binding of PR.
Finally, it is interesting to note that the algorithm is not always
preserving amino acid side chain changes through the generations.
For example, I84 V on chain A is introduced in M18 and kept in
M19, M20 and M21, but later reverted. Possibly, an isoleucin in
position 84 is energetically more favorable, given the other side
chain changes.
Table 4. FMO computed binding energies of HIV-1 protease WT and selected drug resistance mutant PRs (DR set).
PR Peptides
NC-p1WT NC-p1K436R NC-p1A431V poly-Ala poly-Arg
WT-PR 249 270 256 215 241
D30N 229 244 236 215 223
I50L 264 249 254 216 249
I50V 254 246 252 218 234
V82A 245 254 252 216 238
I84V 246 275 235 223 238
I84V L90M 255 267 255 220 246
Computed binding energies (kcal/mol) of WT-PR and selected drug resistance mutant proteases in complex with NC-p1 as wild type, K436R and A431V drug resistance
associated mutant peptides, poly-alanine and poly-arginine peptides.
doi:10.1371/journal.pone.0095833.t004
In Silico Prediction of Mutant HIV-1 Proteases
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Conclusions
In the first part of this study we developed a methodology to test
the cleavability of a peptide by HIV-1 protease (Tables 1 and S6 in
File S1), solely based on the binding energy between the enzyme
and the substrate. The methodology can also be applied to mutant
PRs, Table 3. The technique is based on a PyRosetta algorithm
generating, iteratively, optimized structures, coupled with an
energy re-evaluation at a higher level of theory (FMO/PCM
MP2/6-31G(d)).
In the second part of this study, the optimization algorithm was
extended to permit the stochastic change of the side chain of
selected residues, in order to better bind a given target peptide
sequence. The selected target peptide was required to be different
from the endogenous peptides. The desired outcome was a mutant
PR with stronger and weaker predicted binding energy for the
target and endogenous peptides, respectively, compared to WT-
PR. The mutant PRs M22 and M24 generated through Strategy2
exhibit such desired characteristics (Table 6). We analyzed the
backbone structure of WT-PR and M24 and found no major
differences, thus indicating that M24 should retain the general
structure features of wild type HIV-1 protease. Strategy2
algorithm is able to predict mutations outside the usual set of
residues involved in drug resistance, possibly giving an ulterior
insight into the binding process of HIV-1 protease.
Ongoing experimental studies will show if and how well M22
and/or M24 bind and cleave the target sequence. Our current
experimental and computational studies are also aimed at
analyzing M24 mutations, residue by residue and in combination,
and their possible role in binding the target sequence. It is our
hope that the experimental tests will provide enough information
to be used to further improve the mutant generating algorithm. If
the combination of computational algorithm and experimental
verification is successful it will maybe permit the design of mutant
PRs specific for any given substrate peptide.
Computational Methods
In general, the activity of an enzyme towards two similar
substrates is regulated by (i) how good the enzyme-substrate
binding is and (ii) how efficient the enzymatic reaction is.
Following the dynamic substrate envelope hypothesis [9,10], we
Table 5. Strategy2 suggested mutant PRs.
Mutant ID Chain A Chain B Mutation Scheme Notes
M17 A28S D30T A28S D30T K45M I50L V82F F After one mutation step
M18 A28S D30T I50L P81D V82R I84V A28S D30T K45M I50L V82Y F After one mutation step
M19 A28S D30T I50L P81D V82R I84V A28S D30T K45A I50L V82Y I84L F After two mutation steps
M20 A28S D30T I50L P81D V82R I84V A28S D30T K45D I50L V82Y I84L F After three mutation steps
M21 A28S D30T I50L P81L V82Y I84V A28S D30T K45D I50L V82Y F After four mutation steps
M22 A28S D30T I50L P81L V82Y A28S D30T K45A I50L V82Y F After five mutation steps
M23 A28S D30T I50L P81L V82Y A28S D30T K45A I50L V82Y F After six mutation steps
M24 A28S D30T K45A I50L P81L V82Y A28S D30T K45A I50L P81L V82Y – Homodimer of M22
M17–M23 represent the subsequent generations of mutant PRs suggested by Strategy2. All mutant enzymes were generated following Scheme F.
doi:10.1371/journal.pone.0095833.t005
Table 6. FMO computed binding energies of HIV-1 protease WT and Strategy2 mutant PRs.
PR Peptides
Target poly-Ala poly-Arg TF-PR CA-p2 p2-NC
WT-PR 29 215 241 262 252 272
Gen 1
M17 234 213 247 268 282 274
M18 224 219 245 282 262 263
Gen 2
M19 217 2 1 267 246 281
Gen 3
M20 223 22 219 267 233 284
Gen 4
M21 220 2 7 237 232 218
Gen 5
M22 229 26 10 242 225 230
M24 229 211 7 244 233 233
Computed binding energies (kcal/mol) of WT-PR and Strategy2 mutant proteases in complex with Target, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides.
doi:10.1371/journal.pone.0095833.t006
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assume a correlation between the binding of different peptides to
PR and cleavability of the former. Thus we compute qualitative
binding energies, on the premise that lower binding energy equals
better cleavability.
Binding Energies
PyRosetta Algorithm. The structure of wild type (WT) HIV-
1 protease in complex with different octa-peptides was optimized
using PyRosetta 1.1 [16], a python script-based interface to
Rosetta [17], and the algorithm depicted in Figure 4. The
algorithm is based on the flexible peptide-docking algorithm used
by Chaudhury and Gray [15] to identify in WT HIV-1 protease
the active-site residues mostly involved in the discrimination of
cleavable and non-cleavable peptides. Following their algorithm,
the HIV-1 protease – peptide complexes are represented in atomic
resolution, as opposed to a coarse-grain representation. With
respect to the algorithm described in [15], our algorithm (Figure 4)
has a larger number of cycles (86466 = 192 compared to
8612 = 96), and more ‘small’ and ‘shear’ moves for the
perturbation of both the side chain and the backbone atoms.
The side chain conformations are further optimized through a
repacking algorithm [32] and using the extended Dunbrack library
[33,34]. The moves are applied to all residues of the substrate
peptide plus a selected number of residues of the protease, with the
following criterion: all residues inside a 5 A˚ distance from any
atom of the substrate peptide, plus all the residues reported as
active by Chaudhury and Gray [15], plus their +1 neighbours,
plus if one residue is included on only one chain it is made to be
included in both. After the moves, an energy minimization step is
performed, based on the Davidon-Fletcher-Powell method
[35,36]. Each structure is then accepted or rejected based on a
Monte Carlo (MC) criterion depending on the standard
RosettaDock energy function [32,33,37–39]. Along the optimiza-
tion a temperature gradient was applied, from an initial value of
kT = 3.0 to 1.0, unless differently stated. 500 decoy structures were
generated using 5 parallel algorithm runs, each producing 100
structures.
The main difference with the algorithm of [15] is that after the
algorithm produced 500 decoy structures, the lowest in energy is
chosen and used as a starting structure for another cycle of
optimization. This process is repeated K times, until convergence.
It was found that, after at least 5 cycles, the computed
RosettaDock energy did not change between subsequent cycles
as soon as all 5 parallel runs of a single cycle produced structures
with the same energy. Consequently, in order to render as
automatic as possible the algorithm, the fact that Kw5 and that
each parallel run produced, as best structure, a decoy with the
same energy was taken as a mark for convergence. It was found
that, on average, a value of K~20 was sufficient. As an example,
Figure 5 reports the energy of WT-PR bound to TF-PR along the
optimization. The points at each step corresponds to the
RosettaDock energy of the lowest in energy decoy out of the
500 computed at that particular step. Such structure would then
be used as starting point for the next cycle. At the end of the K
cycles the lowest in energy decoy is chosen as the PyRosetta
optimized structure.
The same algorithm was also used for the optimization of
mutant HIV-1 proteases (vide infra), the octa-peptides alone, and
the protease alone as apo-protein.
The starting structures were prepared from that of HIV-1
protease in complex with an inhibitor (PDB accession code 1HXB
[40]), considered as apo-protein. In order to place the substrate
peptide, the structure of a D25N deactivated protease in complex
with the natural substrate peptide p2-NC (PDB accession code
1KJ7 [9]) was aligned with respect to the backbone atoms of the
protease (RMS = 0.436 A˚). The starting structure was then
composed using the apo-protein from 1HXB and the substrate
peptide from 1KJ7. All subsequent protease-peptide complexes
were created starting from this structure and mutating the peptide
accordingly. See Tables S1, S3 and S4 in File S1 for a complete list
of the considered substrate peptides. Hydrogen atoms were added
through the program Pymol [41].
Further Structures Optimization and Energetic Re-
evaluation. The position of the hydrogen atoms of each
PyRosetta generated structure was optimized using Open Babel
[42] with the MMFF94 [43–47] force field. The energy of each
structure was finally re-evaluated at the higher level of theory
‘FMO2-MP2/6-31G(d)/PCM [1]’. Single point energy evalua-
tions were carried out using the fragment molecular orbital (FMO)
approximation [48,49], as implemented in GAMESS [50]. Each
FMO calculation was carried out at the MP2 level of theory [51]
with the 6–31 G(d) basis set [52,53] and the Polarazible
Continuum Model (PCM) approximation [54,55]. Pairs of
fragments separated by more than two van der Waals radii were
calculated using a Coulomb expression for the interaction energy
and ignoring correlation effects (RESDIM = 2.0 RCORSD = 2.0
in $FMO). The input files for the FMO calculations were prepared
using the program FRAGIT [56].
Binding Energies Evaluation. The re-evaluated energy of
every optimized structure was used to compute the binding energy
of PR with different substrate peptides. The binding energy (EBind )
of HIV-1 protease (wild type or mutated) and a peptide was
evaluated with equation (1), where EComplex is the energy of the
complex, EAPO the energy of the protease optimized as apo-
protein, EPep the energy of the optimized peptide.
EBind~EComplex{ EAPOzEPep
  ð1Þ
These binding energies can not be directly compared to
experimental values, for which a much more complex and
accurate methodology is required [57]. These energies were used
only to qualitatively compare different PR – peptide combinations.
Mutation Algorithm
A similar procedure as that described in Figure 4 was used to
produce mutant HIV-1 proteases, possibly capable of cleaving a
given peptide different from the endogenous substrate peptides.
The general idea was to ‘expose’ the protease to a different peptide
Figure 2. Backbone difference between PyRosetta computed
structures of WT-PR and M24. The optimized structures of WT-PR
and M24 binding the target peptide were aligned with respect to their
a-carbon atoms using PyMol. The backbone of M24 (red) is almost
coincident with that of WT-PR (green) with a RMS of 0.227 A˚.
doi:10.1371/journal.pone.0095833.g002
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and allow some residues to change in order to accommodate it
better. A target octa-peptide was chosen: HLSF*MAIP, where the
* symbol indicates the desired cleaving site. The peptide sequence
was extracted from that of k-casein.
The assumption behind the algorithm is that lowering the
energy of the PR – peptide complex by changing the side chains of
selected residues would decrease also the binding energy, thus
increasing the cleavability.
Two different methodologies were designed to predict mutant
PRs, Strategy1 and Strategy2. The Strategy1 mutation algorithm
is depicted in Figure 6. Each optimization step corresponds to the
algorithm of Figure 4. In the mutation steps (also based on the
previous algorithm), the Dunbrack library of rotamers includes all
rotamers of all amino acids, but only for a selected number of
residues. The six specificity determining residues, as found by [15],
are chosen to be altered. In other words, during the mutation step,
whenever one of the alterable residues is being optimized, the
random choice of a test rotamer is among all possible amino acids.
In Scheme A alterations are allowed on all 6 residues on both
chains, for a total of 12 alterable residues. Thus, side-chain
perturbation and repacking rotamer choice is performed randomly
selecting among 12620 = 240 possible amino acids. In Scheme B
only alterations on L76 and V82 of Chain A and D30, I47, G48,
and I84 of Chain B are allowed, for a total of 6 alterable residues.
Figure 3. Spatial disposition of the residues changed by Strategy2. The six residues of chain A (top) and 6 residues of chain B (bottom) are
highlighted in ball-and-sticks. The reported structure (as semi-transparent cartoon) is that of WT-PR optimized when binding the target peptide (only
the backbone is shown in sticks). Figures S3–S14 in File S1 report the full residue by residue changes. A movie showing the three dimensional
structure is included as Supporting Material in File S1.
doi:10.1371/journal.pone.0095833.g003
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In this case, side-chain perturbation and repacking rotamer choice
is performed with a random selection among 6620 = 120 possible
amino acids. Each mutation step took ca. 40 hours on 5 cpus to
produce 500 decoys. The lowest energy decoy is then chosen as
starting structure for the next step. The energy of the structure is
evaluated with the standard RosettaDock energy function. The
residue reference energy part of the energy function [32] takes into
account also the differences between different amino acids. In
other words, energy differences between two mutant structures
originates solely from different side chain interactions rather than
from a different number of atoms.
Both the mutation and the optimization steps were repeated K
0
and K times, respectively. The mutation cycles are considered
converged once two following cycles do not introduce new
mutations. Different values of K and K
0
were found necessary to
reach convergence. After a series of mutation cycles (K
0§8), a
series of optimization cycles was performed (K§8), followed by
another usually shorter mutation cycle (K
0ƒ3) and finally a short
optimization cycle (Kƒ3).
Among the naturally cleaved peptides, TF-PR (sequence
SFNF*PQIT) was chosen as a starting substrate peptide, since it
is the most similar, in terms of conserved residues, to the target
peptide (sequence HLSF*MAIP). Consequently, the optimized
structure of WT protease in complex with the TF-PR peptide was
chosen as starting template. The substrate peptide sequence was
altered one amino acid at the time, as reported in Table S10 in
File S1. After each peptide alteration, a series of protease mutation
and optimization cycles were performed. Once convergence was
reached, a new peptide single amino acid change was introduced
and the procedure repeated. Different mutant PRs were obtained
from different runs by changing a few parameters, e.g. the initial
temperature of the simulation. These parameters are specified in
Table S7 in File S1. Some mutant PRs were also produced by
‘exposing’ the protease directly to the target peptide without prior
intermediates (mutation Scheme F). This last process required a
higher number of K
0
cycles (K
0§15), but without having to cycle
through one substrate peptide residue at the time.
All mutant PRs obtained through Strategy1 were heterodimers.
By simply equalizing alterations on both chains a number of extra
homodimer mutant PRs were also obtained. These structures were
subsequently optimized as previously described.
In Strategy2 the number of residues allowed to change was
increased in order to include all amino acids residing inside a 3 A˚
radius from the TF-PR peptide. In other words, we chose those
residues with at least one atom that is distant at most 3 A˚ from any
atom of the substrate peptide. The specificity determining residues
were also included in the set of alterable amino acids, if not already
present. The residues Asp25, Thr26 and Gly27 of both chains
were excluded from the set, since they represent the catalytic triad
[5]. The full set of 26 residues is reported in Table S9 in File S1.
Thus, side-chain perturbation and repacking rotamer choice is
performed randomly selecting among 26620 = 520 possible amino
acids. The mutant PRs were generated using the target peptide
directly (Scheme F). Each mutation step took a bit more than 3
days on 5 cpus to produce 500 decoy structures. An initial
temperature of 9 kT was usued. K
0
= 6 mutation cycles were
performed. The lowest in energy decoy after each mutation step
was subsequently optimized (two after the first step). The sixth
mutation step did not introduce any new mutation in PR and the
mutation cycle was stopped.
Figure 4. PyRosetta based optimization algorithm. w, y, x
represent perturbations applied to both backbone and side chain
dihedral angles. MC criterion stands for a Monte Carlo based check of
decoy structures.
doi:10.1371/journal.pone.0095833.g004
Figure 5. Optimization algorithm convergence. Example of
energy convergence during the various macro cycles of the optimiza-
tion algorithm for WT-PR in complex with TF-PR peptide. Each point
along the graph corresponds to the energy (computed with the
RosettaDock energy function) of the lowest in energy decoy out of 500
produced during each of the K steps.
doi:10.1371/journal.pone.0095833.g005
Figure 6. PyRosetta based mutation algorithm. The optimization
step is the algorithm presented in Figure 4. In the mutation step the
side chain perturbation for the six specificity determining residues is
among all possible rotamer of all 20 amino acids.
doi:10.1371/journal.pone.0095833.g006
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Also the mutant PRs obtained through Strategy2 were
heterodimers. Only the homodimer of the final mutant PR was
considered, see Table 5.
Supporting Information
File S1 Tables S1–S11, Figures S1–S14, a movie showing the
three dimensional structure of WT-PR bound to the target
peptide, with highlighted the residues that are changed in M24.
(PDF)
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